Table 2.
Frequencies of patients who received the respective treatments. The patients are categorized here into four mutually exclusive (distinct) patient groups according to the number of documented therapy lines. The percentages of patients treated are marked in bold. The numbers and percentages of treated patients refer to the cumulative number of patients treated up to the highest documented therapy line. For example, in the group of patients with three therapy lines documented and treated after 2013, 33 patients have been treated with trastuzumab in one of the first three therapy lines.
| Therapy | Patients Treated Before 2012 | Patients Treated Crossing 2013 | Patients Treated After 2013 | |||
|---|---|---|---|---|---|---|
| Not Treated | Treated | Not Treated | Treated | Not Treated | Treated | |
| Trastuzumab (H) | ||||||
| treatments in patient group 1 a | 4 (19) | 17 (80.9) | 0 (0) | 6 (100) | 28 (20.4) | 109 (79.5) |
| treatments in patient group 2 b | 0 (0) | 6 (100) | 2 (13.3) | 13 (86.6) | 11 (15) | 62 (84.9) |
| treatments in patient group 3 c | 0 (0) | 4 (100) | 3 (15.7) | 16 (84.2) | 6 (15.3) | 33 (84.6) |
| treatments in patient group 4 d | 3 (20) | 12 (80) | 8 (18.1) | 36 (81.8) | 7 (18.4) | 31 (81.5) |
| Trastuzumab + pertuzumab (PH) | ||||||
| treatments in patient group 1 a | 19 (90.4) | 2 (9.5) | 3 (50) | 3 (50) | 51 (37.2) | 86 (62.7) |
| treatments in patient group 2 b | 6 (100) | 0 (0) | 11 (73.3) | 4 (26.6) | 21 (28.7) | 52 (71.2) |
| treatments in patient group 3 c | 4 (100) | 0 (0) | 13 (68.4) | 6 (31.5) | 12 (30.7) | 27 (69.2) |
| treatments in patient group 4 d | 15 (100) | 0 (0) | 28 (63.6) | 16 (36.3) | 14 (36.8) | 24 (63.1) |
| Lapatinib (L) | ||||||
| treatments in patient group 1 a | 20 (95.2) | 1 (4.7) | 5 (83.3) | 1 (16.6) | 134 (97.8) | 3 (2.1) |
| treatments in patient group 2 b | 6 (100) | 0 (0) | 12 (80) | 3 (20) | 65 (89) | 8 (10.9) |
| treatments in patient group 3 c | 3 (75) | 1 (25) | 15 (78.9) | 4 (21) | 30 (76.9) | 9 (23) |
| treatments in patient group 4 d | 8 (53.3) | 7 (46.6) | 22 (50) | 22 (50) | 18 (47.3) | 20 (52.6) |
| Trastuzumab emtansine (T-DM1) | ||||||
| treatments in patient group 1 a | 21 (100) | 0 (0) | 6 (100) | 0 (0) | 131 (95.6) | 6 (4.3) |
| treatments in patient group 2 b | 6 (100) | 0 (0) | 10 (66.6) | 5 (33.3) | 49 (67.1) | 24 (32.8) |
| treatments in patient group 3 c | 4 (100) | 0 (0) | 8 (42.1) | 11 (57.8) | 21 (53.8) | 18 (46.1) |
| treatments in patient group 4 d | 14 (93.3) | 1 (6.6) | 21 (47.7) | 23 (52.2) | 18 (47.3) | 20 (52.6) |
a Group 1 is the patient population for which only the 1st therapy line is documented. These patients are not part of groups 2–4; b Group 2 is the patient population for which only the 1st and the 2nd therapy lines are documented. These patients are not part of the other groups. c Group 3 is the patient population for which only the 1st, 2nd and 3rd therapy lines are documented. These patients are not part of the other groups. d Group 4 is the patient population for which the 1st to the 4th therapy lines are documented. These patients are not part of the other groups.